P8RI (D-P8RI) is a CD31 biomimetic peptide and agonist that specifically targets the juxtamembrane amino acid sequence of the ectodomain of CD31. By restoring the CD31 inhibitory pathway, P8RI exhibits immunosuppressive properties.

P8RI (D-P8RI) was designed as a retro-inverso peptide with all-D-amino acids allowing to maintain bioactivity and to confer resistance towards plasma proteases[1].

P8RI (2.5 mg/kg; s.c.; daily from 7 to 28 after the occurrence of ADIM) prevents aneurysmal transformation by promoting the resolution of intramural hematoma and the production of collagen in dissected aortas in vivo, associated with enrichment of M2 macrophages at the site of injury[3]. Animal Model: Apo E -/- mice (male, 28-week-old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))[3]Dosage: 2.5 mg/kg Administration: Subcutaneous injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II) Result: Aneurysmal transformation was significantly reduced.